The purpose of the study is to identify cardiovascular risk factors, especially modifiable ones, associated with increased risk in very late onset cognitive decline, dementia, and Alzheimer's disease (AD). Unlike the recent rapid progress in the genetics of AD, there is virtually no definitively identified non-genetic risk factor for AD other than age. However, recent evidence suggesting cardiovascular risk factors may be associated with dementia and AD is highly intriguing not only because the widespread prevalence of such factors, especially in the very old, might plausibly account for a large proportion of cases, but also because many of them are modifiable. Hence if cardiovascular risk factors do indeed increase risk for dementia and AD, identifying them offers the prospect of real public health gains in this area. The search for such risk factors among the oldest old may be valuable because the incidence of AD and other dementias is at its peak in this group and genetic factors appear to play a minimal role suggesting that this group may be most likely to reveal other, potentially more tractable risk factors. The five year study will focus on a cohort of 520+ very elderly (mean age >85) non-demented residents of an apartment complex for the independent elderly (Kitay House) and an affiliated nursing home (Jewish Home and Hospital for the Aged [JHHA]). At Kitay House, in years 1-4, the Clinical Support Core will identify and assess non-demented residents who will be followed annually by the Core in serial assessments to determine the incidence of cognitive decline, AD, vascular and other dementias. Similarly, a smaller group of non-demented residents of the JHHA will also be ascertained and serially assessed.
An aim of the project will be to collect cardiovascular risk factor information from these residents through a physician's physical examine and medical history, biological assays, chart review, and direct interviews. These data will then facilitate the testing of our hypothesis that these factors increase the risk of cognitive decline, dementia in general, and AD. An evaluation of these risk factors for mixed dementia and vascular dementia is also of interest, but these aims are subsidiary, because it is possible that the number of such cases may be small, providing limited statistical power.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-19
Application #
6593369
Study Section
Project Start
2002-06-01
Project End
2003-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
19
Fiscal Year
2002
Total Cost
$196,218
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960

Showing the most recent 10 out of 555 publications